FILTER
LATEST INTERVIEWS
Gil Roth
PRESIDENT, PHARMA & BIOPHARMA OUTSOURCING ASSOCIATION (PBOA)
PBOA explains why the CDMO sector enjoys a higher profile.
Ng Boon Hai
VICE-PRESIDENT SOUTHEAST ASIA CLUSTER, AIR LIQUIDE
Air Liquide continues to expand its presence in Singapore after 110 years on the island.
Debbie Hart
FOUNDING PRESIDENT & CEO, BIONJ
BioNJ relates how New Jersey’s thriving life sciences sector is benefitting from a tremendous boost.
Zoe Phillips Takyi - Appiah
SENIOR PARTNER, JLD AND MB LEGAL CONSULTANCY
JLD and MB Legal Consultancy comment on the current investment climate in Ghana’s extractive industries.
Minister Arc. Olamilekan Adegbite
MINISTER OF MINES AND STEEL DEVELOPMENT, NIGERIA
Nigeria’s Minister of Mines and Steel Development explains how the country is eagerly luring investors to its under-developed mining sector.
Marie-Claire Yaya
CEO, ITM HOLDING
ITM Holding describes the services that it is bringing to DRC and intends to offer across Africa.
Ow Kai Onn
VICE PRESIDENT & HEAD, CHEMICAL AND MATERIALS, ECONOMIC DEVELOPMENT BOARD (EDB)
Singapore’s Economic Development Board (EDB) speaks to GBR about the recovery of the island nation’s chemical industry and how it intends to maintain its leading position in South East Asia.
Michael Gribbons
PRESIDENT, CEO & CO-FOUNDER, MAESTRO DIGITAL MINE
Maestro Digital Mine is witnessing record levels of demand for its mine hardened IIoT devices.
Don Bubar
PRESIDENT & CEO, AVALON ADVANCED MATERIALS
Avalon Advanced Materials explains how North America must facilitate the development of a complete supply chain in order for the development of battery materials to advance.
Eugenio Manzano
EXECUTIVE DIRECTOR, POCHTECA
"Pochteca is expanding operations to reach 10 countries in the Americas as well as expanding services to meet evolving demand."
MACIG
SPANISH
SUBSCRIBE TO OUR NEWSLETTER
RECENT PUBLICATIONS
United States Life Sciences 2025 - Digital Interactive
Resilience amid uncertainty. These words encapsulate the US life sciences sector as it navigates 2025. While the industry has largely rebounded from the recent biotech bear market, with clinical trial starts and funding showing signs of rebound, headwinds remain.
Resilience amid uncertainty. These words encapsulate the US life sciences sector as it navigates 2025. While the industry has largely rebounded from the recent biotech bear market, with clinical trial starts and funding showing signs of rebound, headwinds remain.
PARTNER EVENTS
SUBSCRIBE TO OUR
NEWSLETTER
- Get GBR content delivered to your inbox
- Receive industry based news
- Completely free, e-mail only
